Febuxostat: The evidence for its use in the treatment of hyperuricemia and gout

Core Evidence

Volumn 4, Issue , 2009, Pages 25-36

  Gaffo, Angelo L ^a   Saag, Kenneth G ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

Evidence; Febuxostat; Gout; Hyperuricemia

Indexed keywords

ALLOPURINOL; AMOXICILLIN; AMPICILLIN; AZATHIOPRINE; BENZBROMARONE; COLCHICINE; FEBUXOSTAT; FENOFIBRATE; GLUCOCORTICOID; HEPARIN; INDOMETACIN; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PLACEBO; PROBENECID; RIFAMPICIN; SALICYLIC ACID; SULFINPYRAZONE; TETRACOSACTIDE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; ACUTE GOUT; CHRONIC GOUT; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GOUT; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERURICEMIA; LEUKOPENIA; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LIVER TOXICITY; NEPHROLITHIASIS; NEPHROTIC SYNDROME; ORGAN TRANSPLANTATION; PROPHYLAXIS; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SOLID ORGAN TRANSPLANT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 77951229146     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Becker MA, Meenakshi J. Clinical gout and the pathogenesis of hyperuricemia. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology Philadelphia. Lippincott Williams & Wilkins; 2005, p. 2 v. (xxiv, 2699, 2108 p).
2. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum. 2007;58:26-35.
3. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403-2406.
4. Darmawan J, Valkenburg HA, Muirden KD, Wigley RD. The epidemiology of gout and hyperuricemia in a rural population of Java. J Rheumatol. 1992;19:1595-1599.
5. Brauer GW, Prior IA. A prospective study of gout in New Zealand Maoris. Ann Rheum Dis. 1978;37:466-472. (Pubitemid 9074991)
6. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin. 2006;22:1381-1389. (Pubitemid 44085590)
7. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health. 2007;10:231-237. (Pubitemid 47077244)
8. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008;67:1310-1316.
9. Stamp L, Searle M, O'Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005;65:2593-2611. (Pubitemid 43049954)
10. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med. 1987;82:421-426.
11. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006a;65:1312-1324.
12. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46:1372-1374.
13. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-451. (Pubitemid 126528536)
14. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50:937-943. (Pubitemid 38326194)
15. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006b;65:1301-1311.
16. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-2432. (Pubitemid 39610535)
17. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87-114.
18. Day RO, Miners JO, Birkett DJ, et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol. 1988;26:423-428.
19. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646-1650. (Pubitemid 44168841)
20. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57:545-549.
21. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31:1575-1581. (Pubitemid 39006640)
22. Owens D, Whelan B, McCarthy G. A survey of the management of gout in primary care. Ir Med J. 2008;101:147-149.
23. Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12:61-65. (Pubitemid 44309598)
24. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25-32. (Pubitemid 350298142)
25. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. 2001;44:231-238. (Pubitemid 32113139)
26. Young JL Jr, Boswell RB, Nies AS. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med. 1974;134:553-558.
27. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol. 1979;1:365-374.
28. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56. (Pubitemid 14216359)
29. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986;29:82-87.
30. Emmerson BT, Hazelton RA, Frazer IH. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum. 1988;31:436-440. (Pubitemid 18091669)
31. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134-4139.
32. EBPG RT (European Best Practice Guildes Expert Group for Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.9.2. Haematological complications. Leukopenia. Nephrol Dial Transplant. 2002;17 Suppl 4:49.
33. Fox IH, Kelley WN. Management of gout. JAMA. 1979;242:361-364. (Pubitemid 9233661)
34. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31:643-665.
35. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006;8(Suppl 1):S4.
36. Hahn P, Edwards N. Management of hyperuricemia. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions : a textbook of rheumatology Philadelphia. Lippincott Williams & Wilkins; 2005, p. 2 v. (xxiv, 2699, 2108 p).
37. Conaghan PG, Day RO. Risks and benefits of drugs used in the management and prevention of gout. Drug Saf. 1994;11:252-258. (Pubitemid 24308248)
38. Izzedine H, Brocheriou I, Becart J, Deray G. Probenecid-induced membranous nephropathy. Nephrol Dial Transplant. 2007;22:2405-2406.
39. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278:1848-1855. (Pubitemid 36801423)
40. Becker MA, Schumacher HR, Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005a;52:916-923. (Pubitemid 40372228)
41. Schumacher HR Jr, Becker M, Wortmann RL, et al. Magnetic resonance imaging of gouty tophi during treatment with febuxostat, a non-purine selective inhibitor of xanthine oxidase. Presented at: the Meeting of the American College of Rheumatology; October 16-21, 2004; San Antonio, Texas.
42. Becker M, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients. Presented at: the Meeting of the American College of Rheumatology; October 16-21, 2004; San Antonio, Texas.
43. Wortmann RL, Becker M, Schumacher HR Jr, et al. Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase. Poster presented at: 2004; [need full ref].
44. Schumacher HR Jr, Wortmann RL, Becker M, et al. A phase 2, long term open-label safety and efficacy study of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase. Presented at: the Meeting of the American College of Rheumatology; November 13-17, 2005; San Diego, California.
45. Schumacher HR Jr, Becker M, Wortmann RL, et al. The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study. Presented at: the Meeting of the American College of Rheumatology; November 10-15, 2006; Washington, D.C.
46. Kamatani N, Fujimori S, Hada T, et al. Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemia. Presented at: the Meeting of the American College of Rheumatology; October 23-28, 2003; Orlando, Florida.
47. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005b;353:2450-2461. (Pubitemid 41781828)
48. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-1548.
49. Moreland LW. Febuxostat-treatment for hyperuricemia and gout? N Engl J Med. 2005;353:2505-2507.
50. Chatham WW, Saag KG. Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? Nat Clin Pract Rheumatol. 2006;2:240-241.
51. Gelber AC. Febuxostat versus allopurinol for gout. N Engl J Med. 2006;354:1532-1533; author reply 1532-1533.
52. Becker M, MacDonald P, Hunt B, Lademacher C, Joseph-Ridge N. Gout flare incidence in relation to average serum urate during the first year of urate-lowering therapy. Presented at: the Meeting of the American College of Rheumatology; November 6-11, 2007a; Boston, Massachusetts.
53. Schumacher HR, Becker M, MacDonald P, et al. Febuxostat versus Allopurinol in the treatment of gout in subjects 65 years of age or older. Presented at: Meeting of The European League Against Rheumatism; June 13-16, 2007; Barcelona, Spain.
54. Wortmann RL, Becker M, Schumacher HR Jr, et al. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial. Presented at: the Meeting of the American College of Rheumatology; November 10-15, 2006; Washington, D.C.
55. Becker M, Schumacher HR Jr, MacDonald P, et al. Urate-lowering therapy (febuxostat [FEB] or allopurinol [ALLO]) in subjects with gout: interim results from the febuxostat comparative extension long-term study (EXCEL). Presented at: the Meeting of the American College of Reumatology; Novemeber 6-11, 2007b; Boston, Massachusetts.
56. Kamatani N, Fujimori S, Hada T, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia. Presented at: the Meeting of the American College of Rheumatology; October 16-21, 2004a; San Antonio, Texas.
57. Kamatani N, Fujimori S, Hada T, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia. Presented at: the Meeting of the American College of Rheumatology; October 16-21, 2004b; San Antonio, Texas.
58. Becker M, Schumacher HR Jr, Espinoza L, et al. A phase 3 randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat and allopurinol in subjects with gout. Presented at: the Meeting of the American College of Rheumatology; October 24-29, 2008; San Francisco, California.
59. EMA (European Medicines Agency). Available at: http://www.emea.europa.eu/ humandocs/Humans/EPAR/adenuric/adenuric.htm (accessed November 10, 2008).
60. NICE (National Institute of Health and Clinical Excellence) 2008a. Available at: http://www.nice.org.uk/nicemedia/pdf/STAFebuxostatGoutFAD.pdf (accessed November 10, 2008).
61. NICE (National Institute of Health and Clinical Excellence) 2008b. Available at: http://www.nice.org.uk/guidance/index.jsp?action=folder&o= 42356 (accessed November 10, 2008).
62. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20:391-395.
63. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359. (Pubitemid 34251969)
64. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888-2897. (Pubitemid 35386908)
65. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474-480. (Pubitemid 37237341)